Every 424B that AbbVie Inc. (ABBV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ABBV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABBV filings page.
AbbVie Inc. is issuing a total of $10.0 billion of unsecured senior notes in nine series, including $500 million floating rate notes due 2028 and eight fixed-rate tranches maturing between 2028 and 2066 with coupons ranging from 4.500% to 6.100%. The notes rank equally with AbbVie’s existing unsecured senior debt and are structurally subordinated to obligations of its subsidiaries.
AbbVie expects net proceeds of approximately $9.93 billion, to be used to fund a portion of the $10.9 billion cash acquisition of Apogee Therapeutics, related fees, and for general corporate purposes, including potential debt repayment. If the Apogee acquisition is not pursued or the acquisition agreement is terminated, AbbVie must redeem the floating-rate and shorter- to medium-term fixed-rate notes at 101% of principal plus accrued interest, while the 2056 and 2066 notes are excluded from this special mandatory redemption.
As of June 30 2026, AbbVie had $68.4 billion of unsecured senior notes outstanding and, on a pro forma basis including this offering, total indebtedness would be about $80.4 billion. The company also has a $10.0 billion 364-day delayed draw term loan, $8.0 billion of unused revolving credit capacity, and a $2.0 billion term loan due 2027.
AbbVie Inc. is conducting a primary offering of multiple series of unsecured senior notes, including floating-rate and fixed-rate tranches, under its effective shelf registration. The notes rank equally with AbbVie’s existing unsecured, unsubordinated debt and are issued in minimum denominations of $2,000.
AbbVie expects to use the net proceeds primarily to fund a portion of the cash consideration for its pending acquisition of Apogee Therapeutics, Inc. and related fees, and for general corporate purposes, which may include repaying or repurchasing outstanding debt. The Apogee acquisition agreement values Apogee at approximately $10.9 billion.
If AbbVie announces that the Apogee acquisition agreement is terminated or that it will not pursue the transaction, it must redeem specified "Mandatorily Redeemable" series of notes at 101% of principal plus accrued interest under a Special Mandatory Redemption. Other long-dated series are not subject to this feature. The notes are not secured, will not be listed on an exchange, and there is no escrow of offering proceeds for investors’ benefit.
AbbVie Inc. is offering $8,000,000,000 aggregate principal amount of senior notes across seven series.
The offering includes floating rate notes due 2028 and six fixed‑rate series maturing from 2028 to 2066, with coupons ranging from 3.775% to 5.650%. The issuer expects net proceeds of approximately $7.95 billion, which it intends to use to repay amounts outstanding under its 364‑Day Delayed Draw Term Loan Facility (of which $2.0 billion is currently outstanding) and for general corporate purposes, which may include repayment or repurchase of outstanding debt.
AbbVie Inc. is marketing a multi-series offering of senior unsecured notes, including a floating-rate series linked to Compounded SOFR and several fixed-rate series, under a preliminary prospectus supplement dated February 24, 2026. The company states it intends to use proceeds to repay borrowings under its 364-Day Delayed Draw Term Loan Facility, of which $2.0 billion is outstanding, and for general corporate purposes. The notes will be unsecured, rank equally with existing unsecured senior debt, be issued in minimum denominations of $2,000, and may be redeemed at AbbVie’s option on the terms described in the prospectus supplement.